Department of Otolaryngology - Head & Neck Surgery, Auckland District Health Board, Auckland City Hospital, Auckland, New Zealand.
Department of Otolaryngology - Head & Neck Surgery, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
J Otolaryngol Head Neck Surg. 2020 Oct 14;49(1):74. doi: 10.1186/s40463-020-00467-w.
The aim of this study is to assess the feasibility and effectiveness of using peri-operative brachytherapy (BRTx) for positive/narrow margins present post primary surgical resection of oral tongue squamous cell carcinoma (OTSCC).
Prospective single-centre study of patients with OTSCC (T1-3, N0-3, M0) treated with resection of primary tumour ± regional nodal resection and intra-operative insertion of BRTx catheters. BRTx was administered twice daily at 40.8Gy/12Fr for 'Positive' (≤2 mm) margins, at 34Gy/10Fr for 'Narrow' (2.1-5 mm) margins, and not given for 'Clear' (> 5 mm) margins over the course of 5-6 days, 3-5 days post operatively.
Out of 55 patients recruited 41 patients (74.6%) were treated with BRTx, as 12 patients had clear margins and 2 patients had unfavourable tumour anatomy for catheter insertion. EBRTx was avoided in 64.3% of patients. Overall Survival (OS) at 3 and 5 years was 75.6 and 59.1% respectively, while Disease Specific Survival (DSS) was 82.3 and 68.6% at 3 and 5 years respectively. Recurrence and survival outcomes were not associated with margin status or the use of or specific dose of BRTx on Cox regression analysis. Acute and late toxicity secondary to BRTx was minimal.
The use of BRTx after primary OTSCC resection with positive/narrow margins ± EBRTx to the neck ± CTx achieves outcomes comparable to traditional treatment of surgery followed by re-resection or EBRTx ± CTx. Morbidity associated with oral cavity EBRTx or secondary resection and reconstruction is thus avoided. Both acute and late toxicity rates are low and compare favourably with other BRTx OTSCC studies.
Retrospectively registered. https://www.mcgill.ca/rcr-rcn/files/rcr-rcn/2017.06.05_rcn_hn.pdf .
本研究旨在评估口腔舌鳞状细胞癌(OTSCC)术后原发肿瘤切除后,使用围手术期近距离放射治疗(BRTx)处理阳性/窄切缘的可行性和有效性。
对 T1-3、N0-3、M0 期 OTSCC 患者进行前瞻性单中心研究,这些患者接受原发肿瘤切除术±区域淋巴结切除术,并在术中插入 BRTx 导管。BRTx 每天两次,40.8Gy/12Fr 用于“阳性”(≤2mm)切缘,34Gy/10Fr 用于“窄”(2.1-5mm)切缘,对于“清楚”(>5mm)切缘,术后 5-6 天内,3-5 天内不给予 BRTx。
在入组的 55 例患者中,41 例(74.6%)接受了 BRTx 治疗,因为 12 例患者切缘清楚,2 例患者肿瘤解剖结构不适合导管插入。64.3%的患者避免了外照射放射治疗(EBRTx)。总生存(OS)率分别为 3 年和 5 年的 75.6%和 59.1%,疾病特异性生存(DSS)率分别为 3 年和 5 年的 82.3%和 68.6%。Cox 回归分析显示,边缘状态、BRTx 的使用或具体剂量与复发和生存结果无关。BRTx 引起的急性和迟发性毒性反应极小。
在原发 OTSCC 切除后,对阳性/窄切缘±颈部 EBRTx±化疗(CTX)使用 BRTx,与传统的手术切除后再次切除或 EBRTx±CTX 治疗相比,可获得类似的结果。因此避免了与口腔 EBRTx 或二次切除和重建相关的发病率。急性和迟发性毒性发生率均较低,与其他 BRTx OTSCC 研究相比具有优势。
回顾性注册。https://www.mcgill.ca/rcr-rcn/files/rcr-rcn/2017.06.05_rcn_hn.pdf。
4。